Animal models of intellectual disability: towards a translational approach by Scorza, Carla A. & Cavalheiro, Esper A.
Animal models of intellectual disability: towards a
translational approach
Carla A. Scorza,I Esper A. CavalheiroI,II
IDisciplina de Neurologia Experimental. Universidade Federal de Sa˜o Paulo/Escola Paulista de Medicina. (UNIFESP/EPM). Sa˜o Paulo, Brazil. IIAPAE – Sa˜o
Paulo, Brazil.
Intellectual disability is a prevalent form of cognitive impairment, affecting 2–3% of the general population. It is a
daunting societal problem characterized by significant limitations both in intellectual functioning and in adaptive
behavior as expressed in conceptual, social and practical adaptive skills. Intellectual disability is a clinically important
disorder for which the etiology and pathogenesis are still poorly understood. Moreover, although tremendous
progress has been made, pharmacological intervention is still currently non-existent and therapeutic strategies
remain limited. Studies in humans have a very limited capacity to explain basic mechanisms of this condition. In this
sense, animal models have been invaluable in intellectual disability investigation. Certainly, a great deal of the
knowledge that has improved our understanding of several pathologies has derived from appropriate animal
models. Moreover, to improve human health, scientific discoveries must be translated into practical applications.
Translational research specifically aims at taking basic scientific discoveries and best practices to benefit the lives of
people in our communities. In this context, the challenge that basic science research needs to meet is to make use of
a comparative approach to benefit the most from what each animal model can tell us. Intellectual disability results
from many different genetic and environmental insults. Taken together, the present review will describe several
animal models of potential intellectual disability risk factors.
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INTRODUCTION
Intellectual disability (ID) is a prevalent form of cognitive
impairment affecting 2–3% of the population in the
industrialized world.1 ID is characterized by significant
limitations both in intellectual functioning and in adaptive
behavior as expressed in conceptual, social and practical
adaptive skills. Moreover, this disability originates before
age 18.2 ID is accepted if the intelligence quotient (IQ) is
lower than 70 and is considered borderline from 70 to 85.3,4
However, a multidimensional framework for understanding
ID depicts how human functioning and the manifestation of
ID involve the dynamic, reciprocal engagement among
intellectual ability, adaptive behavior, health, participation,
context and individualized supports.2 ID is a condition of
great concern for public health and society. The frequency of
ID-related cognitive dysfunction is alarming, considering
that pharmacological intervention is currently non-existent.5
In this context, ID is one of the more important topics in
medical science. It has a complex etiology, with an intricate
interplay of genetic and environmental factors, but the
causal mechanisms are not understood. ID is one of the few
clinically important disorders for which the etiopathogen-
esis is still poorly understood. In this sense, in order to
improve human health, scientific discoveries must be
translated into practical applications. Such discoveries
typically begin at ‘‘the bench’’ with basic research and then
progress to the clinical level, or the patients ‘‘bedside’’.
Scientists are increasingly aware that this bench-to-bedside
approach to translational research is really a two-way
street.6 Scientists provide clinicians with new tools for use
with patients and for assessment of their impact, and
clinical researchers make novel observations about the
nature and progression of a condition, which often
stimulates basic investigation.6 This is the first area of
translational research called ‘‘bench-to-bedside and back’’.
The second area concerns research aimed at enhancing the
adoption of best practices in the community. As an example,
improvements in medical intervention for people with
Down syndrome (DS) have led to a substantial increase in
their longevity, with the estimated life expectancy in
developed countries increasing from an average of 12 years
in the 1940s to an average of 57.8 years for women and 61.1
years for men.7,8 In this sense, animal models have been
invaluable in ID research, since studies in humans have a
very limited capacity to explain basic mechanisms of
disease. Animal models facilitate the developmental analy-
sis of the pathogenesis of abnormalities, particularly during
crucial stages of organogenesis. Even if appropriate tissues
were available in humans, it would be impossible to carry
out any investigations other than static biochemical or
morphological examinations. Consequently, a great deal of
the knowledge that has improved our understanding of
several pathologies has derived from appropriate animal
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models.9 This is certainly the case of pathologies associated
with ID. Arguably the single most essential element in
animal-based research, identifying and selecting the most
appropriate animal model, is also the most challenging.
Different species have species-specific behavioral reper-
toires shaped by their evolutionary history.10 The evolu-
tionary process, by definition, actually refers to the vast
differences that exist between species, and even between
cells within a given species. Thus, modeling of human-like
symptoms in animals should be based primarily on an
expectation of functional similarity of the displayed
behavioral strategy, rather than on one of behavior
equivalency.11 The crucial point is not whether a mouse,
for example, would show a given cognitive impairment,
but, rather, how a cognitive impairment would manifest
itself in this mouse.1 The challenge that basic science
research needs to meet is to make use of a comparative
approach to benefit the most from what each model can tell
us.12 Anyhow, the use of animal models of ID are critical for
determining the basic mechanisms, the neurobiological
substrates and the neural basis of cognitive function as well
as for testing the efficacy of potential therapeutic drugs and
the neurotoxicity of environmental contaminants and drugs
of abuse, among others.
The causes of ID are extremely heterogeneous and
although a cause for ID has been diagnosed in about half of
cases, it has been estimated that half of all cases are due to
environmental factors and half to genetic factors.13
Environmental factors include prenatal exposure of the fetus
to toxic substances (e.g., alcohol, drugs), environmental
contaminants, radiation, infection, malnutrition, illness of
the mother (e.g., exposure to toxoplasmosis, cytomegalovirus
and rubella), etc. In addition, multiple problems, during or
after birth, may also culminate in ID.14 This review shall
describe several animal models of potential ID risk factors.
We have organized this review as shown in Table 1.
GENETIC MODELS
About one-third of all genetic disorders show some
neurological involvement, and many of these represent
neurodegenerative diseases of infancy. Genetic or geneti-
cally influenced conditions rank among the leading causes
of organically based mental retardation. Genetically mod-
ified mice are currently the most commonly used approach
to investigate the role of a specific genetic alteration and to
model pathologies leading to intelligence disability. The
mouse is the most widely used laboratory species to provide
insights linking specific genes to biological functions. Its
wide use is primarily because, among mammals, the mouse
is most amenable to genetic manipulation. Furthermore, our
extensive knowledge of the genome, physiology and
behavior of the mouse makes it possible to interpret the
effects of gene manipulations.1
Down syndrome
DS caused by trisomy of human chromosome 21 (HSA21),
shows an incidence of about 1 in 733 live births.15 DS is
characterized by abnormalities in learning, memory and
language; some degree of intelligence disability is essen-
tially universal.16 Furthermore, individuals with trisomy 21
may show a wide range of pathological features, such as
heart disease, sterility, higher incidence of leukemia,
immune system perturbations and premature aging.
Moreover, they also display muscular hypotonia, deposition
of Alzheimer-like plaques and neurofibrillary tangles in the
brain in the third decade of life.1,17,18 Lejeune et al.19 showed
that an extra copy of human chromosome 21 (now HSA21)
was found in DS. The discovery provided the first evidence
for a genetic substrate of intelligence disability. Although
DS pathogenesis may be complex, all changes must arise
from excess genetic material on HSA21, which encodes 300
known and predicted genes.20 Mouse models of TRS21 have
been developed using syntenies between HSA21 and
MMU16, MMU10 and MMU17. Available mouse models
carry extra fragments of MMU16 or of HSA21 that cover all
of HSA21 (chimeric HSA21) or MMU16 (Ts16); some carry
large parts of MMU16 (Ts65Dn, Ts1Cje, Ms1Cje), whereas
others have reduced contiguous fragments covering the
D21S17-ETS2 region or single transfected genes.21 Among
these, Ts65Dn and Ts1Cje mouse models have been
extensively used to study DS neurobiological phenotypes.
The Ts65Dn mouse, with an extra copy of about 104 mouse
genes orthologous to those on HSA21, shows a number of
developmental and functional parallels with DS. These
include changes in behavior, alterations in the structure of
dendritic spines in the cortex and hippocampus, and failed
hippocampal long-term potentiation (LTP).22–25 Ts1Cje
mice, which are trisomic for a shorter but fully overlapping
segment of MMU16 (about 81 genes), show similar changes,
usually to a somewhat lesser degree.25–29 Several other DS
mouse models have been developed.1 The understanding of
the pathogenicity of the extra genomic material in trisomy
21 has accelerated in recent years because of the recent
advances in genome sequencing, comparative genome
analysis, functional genome exploration and the use of
animal models.30 Aneuploidy, defined as an abnormal
number of copies of a genomic region, is recognized as a
common mechanism of human genetic disease, often
leading to abnormal gene expression patterns with over-
or underexpression of specific genes.31 Surprisingly, a
significant number of human brain cells (both neurons
and non-neuronal cells) can be aneuploidy, and the
resulting genetic mosaicism is a normal feature of the
human central nervous system.32 But, what could be
Table 1 - Animal models.
Genetic models Down syndrome
Fragile X syndrome
Rett syndrome
Inborn errors of metabolism
Environmental
conditions
Neurotoxic insults
Selective neurotoxin-induced model
Neurotoxic treatment of the
developing fetus
Environmental neurotoxic insults
Maternal exposure to infections
Congenital toxoplasmosis
Congenital cytomegalovirus
Congenial rubella
Maternal exposure to teratogenics
Fetal alcohol syndrome
Malnutrition
Brain lesions at early
development
Hypoxic-ischemic insult
Pediatric head trauma
Status epilepticus
Age-related changes Down syndrome Ts65Dn mouse
Transgenic mouse models of amyloid
deposition
Cholinergic receptor knockout mice
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the mechanisms by which the anatomical, chemical and
neurophysiological brain abnormalities underlying ID arise
from deregulation of gene expression? Major questions are
still unanswered. Genetically modified mouse models have
been helping to investigate the contributions of specific gene
alterations and gene–environment interactions to the phe-
notype of several forms of ID.
Fragile X syndrome
X-linked disorders may explain why males show a 25–
35% higher incidence of mental disabilities than females. It
is imperative to gain knowledge of the mechanisms specific
to the X-chromosome (e.g., X-inactivation, gene regulation)
that may be relevant to understanding some forms of X-
linked mental retardation. Fragile X syndrome (FXS) is the
leading cause of heritable intelligence disability, affecting
about 1 in 1400 males and 1 in 2500 females. FXS is caused
by a trinucleotide expansion in the fragile X mental
retardation 1 gene (fmr1) that prevents the expression of
the encoded protein, called fragile X mental retardation
protein (FMRP).33 The genetic defect is an unstable region of
DNA on the X chromosome that becomes highly expanded
when transmitted through the maternal lineage. FXS is a
common form of mental retardation associated with atten-
tion deficit, autistic behavior, hyperactivity and epileptic
seizures.34 The phenotype of FXS is reproduced in fmr1
knockout (KO) mice that, among others, have region-
specific altered expression of some gamma-aminobutyric
acid (GABA) receptor subunits.35,36
Rett syndrome
Rett syndrome (RTT) is an X-linked autism spectrum
disorder found almost solely in females. Clinical character-
istics include abnormal motor gait, stereotypic hand wring-
ing movements and autistic-like behavior. Affected girls also
exhibit speech abnormalities and severe intellectual disability
in most cases.37 One peculiar aspect of this disorder is that
individuals appear normal at birth, then, between 6 and 18
months, they begin to lose some already acquired skills, such
as communication, language and motor coordination.1 RTT is
caused by mutations in MECP2, encoding methyl CpG-
binding protein 2. Since the discovery of MECP2 mutations as
the genetic cause of RTT in 1999,38 the understanding of
MeCP2 function has evolved. In past years, researchers have
produced mice with genetically altered MeCP2 that dis-
played some features of Rett in order to characterize the
biological, pathological and behavioral features of these mice
and have compared them with the human condition.39–41
Combined epigenomic approaches of MeCP2 binding,
methylation and gene expression have demonstrated that
MeCP2 binds preferentially to intergenic and intronic and
sparsely methylated promoters of active genes.42 While
autism is strongly heritable, most cases of autism are
expected to be due to a combination of genetic, environ-
mental and epigenetic factors. As in the case of RTT, genetic
disorders on the autism spectrum affecting epigenetic path-
ways include Angelman, Prader–Willi and 15q duplication
syndromes.42 Thus, armed with intense research, improved
understanding and therapies for RTT, and perhaps a subset
of autism cases, are certain to follow.
Inborn errors of metabolism
Metabolic disorders result from the absence or abnorm-
ality of an enzyme or its cofactor, leading to either
accumulation or deficiency of a specific metabolite.
Optimal outcome for children with inborn errors of
metabolism (IEM) depends upon prompt recognition,
evaluation and management of these disorders.43 Delay in
diagnosis may result in acute metabolic decompensation,
progressive neurologic injury, or even death. Animal
models of metabolic diseases especially focus on the
pathophysiology mechanisms due to imbalances in amino
acids, mucopolysaccharides, purines, lipids and carbohy-
drates, or the dysfunction of cellular organelles (e.g.,
mitochondria, peroxisomes, lysosomes, or Golgi) that
contribute to intelligence and developmental disabilities as
well as to the development of therapeutic strategies (i.e.,
genetic or pharmacological) that aid in the diagnosis and
clinical management of these IEM disorders.44 Specific
examples of metabolic disorders associated with intelligence
disability include phenylketonuria, Lesch–Nyhan, galacto-
semia and adrenoleukodystrophy. In the 70s in Brazil,
Benjamin Schmidt and colleagues started a project called ‘‘A
national plan for study and detection of IEM disorders that
could lead to mental deficiency’’. In the sequence, Brazil
established the first Newborn Screening Programme for
IEM in Latin America for the detection of phenylketonuria
and other IEM capable of causing intelligence disability.45,46
However, today, the few data available lead to the
conclusion that neither newborn screening nor phenylk
etonuria treatment centers cover all the Brazilian cases.47 In
addition, most phenylketonuria patients have to leave their
home states to seek better treatment. Moreover, the required
specific foods are not readily available and are expensive.
New options are being researched, nevertheless, there is
much to be done, mainly on food research and production.47
ENVIRONMENTAL CONDITIONS
There are a host of environmental conditions that affect
biological risk for intelligence and developmental disabil-
ities, among them are (a) neurotoxic insults, (b) maternal
exposure to infections (e.g. toxoplasmosis, cytomegalovirus
and rubella), (c) maternal exposure to teratogenics (e.g.,
alcohol), (d) malnutrition.
Neurotoxic insults
Selective neurotoxin-induced models. Many individuals
with intellectual disability exhibit chronic aberrant behavior
that includes hyperactive, stereotyped, aggressive and self-
injurious behaviors (SIBs).48 SIB is a severe symptom in
Lesch–Nyhan syndrome (LNS), a genetic disorder associated
with deficiency of the enzyme hypoxanthine-guanine
phosphoribosyltransferase (HPRT). HPRT-deficient mice
provided the first demonstration that genetically engineered
mice could be produced as models for a specific human
disease.49 It has been showed that these mice presented
reduced dopamine along with microstructural anatomical
abnormalities, demonstrating that HPRT deficiency leads to a
loss of basal ganglia dopamine through a metabolic
process.50,51 Unfortunately, the main limitation of these mice
is that they do not exhibit some of the more complex aspects
of the LNS phenotype, such as the consequences of uric acid
overproduction or the neurobehavioral syndrome. As a result,
they are of limited value for directly addressing these aspects
of the disorder.51 In this sense, another animal model has been
developed to address the functional significance of dopamine
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loss due to neurobehavioral syndrome.52,53 Because the
prominent neurobiological deficit in LNS is a loss of
dopaminergic neurons, reduction of dopamine 6-hydro-
xydopamine in rats during their development is proposed
as a model of dopamine deficiency in LNS as well as in
individuals with ID and SIB, who may have this
neurotransmitter deficiency. Accompanying the profound
loss of dopamine was an increase in striatal serotonin content.
When the neonatally lesioned rats were challenged as adults
with systemically administered L-DOPA or with muscimol
administration into the substantia nigra reticulata (SNR), SMB
was observed, a response not observed in unlesioned rats.
Since D1-dopamine antagonist blocked the SMB response to
L-DOPA, it was proposed that D1-dopamine receptors were
critical to this behavioral response.52
Neurotoxic treatment of the developing fetus. The adm-
inistration of the alkylating neurotoxin methylazoxymethanol
acetate (MAM, 25 mg/kg sc) to pregnant rats on day 14 or 15 of
gestation induces, in the offspring, a marked microencephaly.54
MAM treatment severely reduces intrinsic neuronal popu-
lations including GABAergic and glutamatergic neurons and
produces a shrunken cortex relatively hyperinnervated by
noradrenergic and cholinergic neurons.55 MAM-induced brain
and behavioral abnormalities provide an animal model of
congenital microencephaly associated with intelligence
disability. The MAM offspring showed no increase in
mortality, but weighed less than controls.56 In addition,
MAM-treated rats display a characteristic hyperactivity. This
hyperactive state was accompanied by notable impairments in
the acquisition of spatial instrumental learning tasks.57 At 2
months of age, the MAM offspring showed pronounced deficit
in learning a water maze; this deficit was not abated when
animals were tested again at 6 months of age, implicating long-
term learning impairments.56
Environmental neurotoxic insults. Neurotoxicity is a
potentially major contributor to the etiology of many types
of intelligence and developmental disabilities. For instance,
models of developmental risk in neurotoxicology have
guided environmental regulation to reduce the likelihood
of neurotoxic effects. On the other hand, models of
developmental risk for ID aim for prevention and early
intervention.58 Over the past three decades, researchers
have found that remarkably low-level exposure to
environmental toxins (e.g., heavy metals, polychlorinated
biphenyls (PCBs), pesticides and herbicides, organic
solvents, environmental tobacco smoke, radiation and
endotoxins) has been linked to intellectual impairments,
learning disabilities, behavioral problems, spontaneous
abortions, or preterm births.59–62 Lead is probably the
most-studied environmental contaminant with respect to
the effects of developmental exposure on cognition in
children or animal models.63 PCBs were banned in the
1970s but their extreme stability allowed them to bio-
accumulate over time, such that they remain one of the most
prevalent environmental contaminants. In this case, animal
research has helped to reveal the differential effects of
neurodevelopmental exposure to PCBs in producing
significant disruption of tasks that require executive
function. As a testament to the usefulness of animal
models, recent follow-up studies of several human PCB
cohorts have employed domain-specific tests such as the
Wisconsin Card Sorting Task64 and continuous performance
tasks64,65 that assess specific aspects of executive control.
These recent assessments have yielded results that are
strikingly consistent with the findings in animal models,
and they highlight the utility of animal models for
predicting specific cognitive domains that are likely to be
impacted in exposed human populations.
Maternal exposure to infections
Congenital toxoplasmosis. Different animal models of
congenital toxoplasmosis have previously been developed
in mice, rats, sheep and guinea pig.66–69 The intracellular
protozoan Toxoplasma gondii is a widespread opportunistic
parasite of humans and animals, and transmission from
animals to humans occurs mainly through oocysts excreted
in the feces of infected cats, and meat products from farm
animals contaminated with viable tissue cysts.70 Pregnant
women who are infected with T. gondii usually remain
asymptomatic, although they can still transmit the infection
to their fetuses, with severe consequences. Primary infection
during pregnancy may result in neonatal death or in severe
congenital defects such as hydrocephalus, mental
retardation and retinochoroiditis, which may occur at
birth or during development.70,71 An effective vaccine
should protect against both acute and chronic infection.
The development of suitable laboratory models is essen-
tial for evaluation of the efficacy of the different recom-
binant subunit vaccine candidates against congenital
toxoplasmosis.
Congenital and perinatal infections with cytome-
galovirus. These are responsible for considerable short- and
long-term morbidity in infants. Cytomegalovirus (CMV) is the
most common congenital viral infection in the developed
world, occurring in 0.5–2% of all births and is a common cause
of neurodevelopmental injury, including mental retardation
and sensorineural hearing loss (SNHL).72 Its clinical
manifestations range from asymptomatic forms (90% of
cases) to severe fetal damage and, in rare cases, death due to
abortion. Furthermore, 10–15% of children who are
asymptomatic at birth may develop late sequelae after a
period of months or even years.73 Animal models are
imperative for the understanding of the host–virus
relationship, which can be exploited to delineate the
mechanisms of pathogenesis to develop therapeutic strategies
to prevent CMV-associated diseases; however, CMVs are
highly species specific. Consequently, each CMV species is
highly adapted to its respective host species and is unable to
infect other, even closely related, hosts.74 Despite being
fascinating from an evolutionary perspective, this restriction
prevents studying CMV in experimental animals. Exceptions
are severely immunocompromised mice, which might allow
partial reconstitution of CMV infection in rodents.74
Congenital rubella syndrome. Most of the enviro-
nmental conditions that affect the biological risk for
intelligence and developmental disabilities are preventable.
In several cases, we, as a society, have been remarkably
successful in preventing their effects. congenital rubella
syndrome (CRS) is a case in point.58 In 1963–65 there was
an epidemic of more than 25 000 cases of CRS in the United
States. However, since the development of the rubella
vaccine in 1969, the incidence has dropped markedly. In
1996 only two cases of CRS were reported in the United
States.58,75 Although Brazil strives to achieve high
immunization coverage through the routine vaccination
program and follow-up campaigns, rubella incidence
increased in the country between 2006 and 2007. For this
reason, in 2008, Brazil launched a major and successful
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national immunization campaign to eliminate rubella and
CRS.76 The main defects associated with CRS are deafness,
eye defects such as cataracts, cardiovascular defects and
central nervous system damage, leading to intelligence
disability.77 It is common to try to study human pathologies
by establishing animal models and certainly that was the case
for CRS. However, several discrepancies have been found in
such studies. Low incidences of cataracts have been reported
in the offspring of infected pregnant rats, rabbits and
monkeys. In contrast, other studies with pregnant animals
(e.g., rats, mice, rabbits, ferrets and monkeys) have not shown
these defects.77 Moreover, abnormalities of the heart, cerebral
blood vessels, and inner ear have been reported in some
studies, but incidences are very low and inconsistent.77 Taken
together, animal models of CRS have not contributed much to
the understanding of their pathogenesis. On the other hand,
the use of animals as models for microbiological infections
has been a fundamental part of infectious disease research.
Thus, the use of animal models for a myriad of bacterial and
viral diseases has led to the production of vaccines for
diseases such as rubella.
Maternal exposure to teratogenics
Fetal alcohol syndrome. Fetal alcohol syndrome (FAS) and
the subsets of individuals with attenuated phenotype
subsumed under the umbrella term of fetal alcohol spectrum
disorder (FASD) provide clinicians with a challenge.78
Individuals with FASD have a higher incidence of
impairments in social adaptive and executive function, and a
higher degree of psychopathology than the general population.
The diagnosis of FAS is based on the occurrence of the
following main symptoms: growth deficiency, dysmorphic
characteristics, central nervous system dysfunctions, intelli-
gence disability, delays in sensorimotor development, attention
deficit, memory disorders, hyperactivity and sleep
disturbances.57 Animal models of FASD have been used to
demonstrate the specificity of the teratogenic effects of alcohol
and some of the underlying changes in the central nervous
system and to explore ways to ameliorate the effects of
alcohol.79 The effects of acute alcohol exposure on specific
days during the embryonic period have been studied fairly
extensively in rodents. Exposure on gestation days 7 and 8 in
mice has shown to result in craniofacial defects similar to those
seen is FAS (e.g., micrognathia, low-set ears, short philtrum,
cleft palate, cleft lip),80 as well and brain anomalies
(e.g., microcephaly, exencephaly, deficiencies in cerebral
hemispheres, striatum, olfactory bulbs, limbic structures,
corpus callosum, lateral ventricles).81 In addition, ocular
defects (anophthalmia, microphthalmia, corneal and lens
anomalies) were associated with acute alcohol exposure on
gestation day 7.82,83 Research has indicated that environmental
enrichment and voluntary exercise have been shown to
ameliorate some of the effects of alcohol during development,
but the roles of enhanced social interactions in the case of
enrichment, social housing and voluntary exercise need to be
more fully delineated.79 In addition, findings of alterations in
maternal care of the alcohol-exposed offspring, epigenetic
effects and their relationship to social behavior in animal
models of FAS are a fruitful area of research.79
Malnutrition
Malnutrition is a worldwide health problem; it exists in
many forms, affects the developing and mature nervous
system, and has acute and chronic health implications.
Malnutrition in children has particularly severe conse-
quences for growth, development, health and well-being,
both on a short- and on a long-term basis, including a high
risk for ID.84 Malnutrition was associated with 54% of
deaths in children in developing countries.85 In developed
countries, childhood malnutrition occurs mostly secondary
to chronic diseases, and it may be aggravated by frequent
hospital stays and diagnostic examinations.86 Most concepts
basic to nutritional investigations have been derived from
animal studies. One distinct characteristic of the research on
protein energy malnutrition and child development is the
selective focus on learning and intelligence. Historically,
work in animals on the functional consequences of energy
and protein deprivation has moved in two directions: one
approach aims the understanding of the developmental
changes in the anatomy and biochemistry of the brain in
experimental animals, while the other one describes the
compromise of behavioral competence.87
BRAIN LESIONS AT EARLY DEVELOPMENT
Hypoxic–ischemic insult
Despite major advances in monitoring technology and
knowledge of fetal and neonatal pathologies, hypoxic–
ischemic encephalopathy (HIE) remains a serious condition
that causes significant mortality and long-term morbidity.
HIE represents a common cause of chronic handicapping
conditions such as cerebral palsy, intelligence disability,
learning disability and epilepsy.88 In an established model
of perinatal HIE brain damage, neonatal animals undergo
carotid artery ligation and hypoxia.89 Animal models have
long been established in the study of neonatal HIE and have
been found suitable for acute and chronic studies. Multiple
therapeutic trials are currently being conducted in animal
models to explore various methods of interventional
therapy against HIE-induced brain damage, with recent
breakthroughs in the demonstration of a neuroprotective
effect of some anti-apoptosis agents and other methods,
such as hypothermia.90–92 Premature births result in an
increased likelihood of intelligence disability. Premature
infants are at high risk of intracranial hemorrhage, asphyxia
and the damaging effects of subsequent HIE.93-95 Existing
models of pediatric hypoxic-ischemic brain damage studied
the effects of glutamate in the postnatal day 7 rat, which is
considered analogous to the newborn human.96 In this
sense, the newborn rat is considered analogous to the late
gestational human. In order to model preterm hypoxic
ischemic brain damage events, it has been proposed that
treatment of newborn rats with muscimol mimics the
initiation of a cell death cascade induced by hypoxia or
injury in premature infants and is analogous to the accepted
method of glutamate administration to the week-old rat pup
to model the newborn human.97 Following this line of
evidence, Nun˜ez et al.97 proposed that the excitatory drive
through the GABAA receptor in early development may be
an important contributor to some forms of brain damage in
premature infants. Furthermore, they also investigated the
effect of postnatal day 0 and 1 muscimol treatment by
performing a pre-weaning version of the water maze and an
open field maze on postnatal day 21, two tasks that are
sensitive to hippocampal function. Taken together, it has
been proposed that rats exposed to excessive GABAA
receptor activation over the first 2 days of postnatal life
serve as a model for pre-term infant brain damage.98
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Pediatric head trauma
Trauma to the developing brain still represents a poorly
explored field. Perinatal head trauma can lead to intellectual
disability among other severe consequences. Head trauma is
the leading cause of death and disability in the pediatric
population.99 In efforts to model pediatric head trauma,
Bittigau et al.99 have developed a model for head trauma in
infant rats in an attempt to study mechanisms of neurode-
generation in the developing brain. In order to morpholo-
gically characterize two distinct types of brain damage they
have demonstrated that, in the developing rat brain,
apoptosis and not excitotoxicity determined neuropatholo-
gic outcome following head trauma. In this sense, they
suggested that radical scavengers and tumor necrosis factor
inhibitors may be useful in the treatment of pediatric head
trauma.100 In this line of evidence, trauma triggers both
excitotoxic and apoptotic neurodegeneration in the devel-
oping rat brain. Excitotoxic neurodegeneration develops
and subsides rapidly (within hours), whereas apoptotic cell
death occurs in a delayed fashion over several days
following the initial traumatic insult.99
Status epilepticus
Status epilepticus (SE) is a medical and neurologic
emergency. In Brazil, the annual occurrence of SE is about
90 000 cases.101 Thus, increased awareness of presentation,
etiologies and treatment of SE is essential in the practice of
critical care medicine. Elegant animal studies in the 1970s
and 1980s revealed significant damage to the brain after
30 min of seizure activity, even with control of blood
pressure, respiration and body temperature.102,103 Damage
to brain tissues resulting from recurrent convulsive seizures
induced by chemicals such as pilocarpine104 or kainic acid
treatment105 may also constitute models of intellectual
disability. These animal models are useful for the study of
SE-induced epileptogenesis and neurological sequelae,
especially during early brain development. Our laboratory
group showed several permanent abnormalities in rats
subjected to multiple SE induced by pilocarpine (ip) during
early development (7–9 days old). In adulthood, these
animals presented frequent episodes of continuous complex
spiking activity and high-voltage ictal discharges and
evidence of severe cognitive deficits.104 SE may result in
important plastic changes in critical periods of brain
maturation leading to long-lasting epileptogenesis, as
manifested by electrographic epileptiform discharges, beha-
vioral deficits and in vitro hyperexcitability of hippocampal
networks.
AGE-RELATED CHANGES
Down syndrome Ts65Dn mouse
As described above, DS results from trisomy of all or part
of human chromosome 21, which generally accounts for
triplication of at least 100 genes. Among these is the gene
encoding amyloid protein precursor (APP), as well as genes
that upregulate APP expression.106 Beta-amyloid is over-
produced in DS individuals throughout life.107 The partial
trisomy 16 (Ts65Dn) mouse is considered the gold standard
of DS mouse models. Ts65Dn mice have an extra copy of the
distal aspect of mouse chromosome 16, a segment homo-
logous to human chromosome 21 that contains much of the
genetic material responsible for the DS phenotype,
including three copies of APP.108 Ts65Dn mice show
developmental delay during the postnatal period as well
as abnormal behaviors in both young and adult animals that
may be analogous to mental retardation. Additionally, by 6
months of age, Ts65Dn mice begin progressive, age-related
decline in choline acetyltransferase levels and cognitive
function, features common to adult DS and Alzheimer
patients.109 Moreover, although the Ts65Dn brain is normal
on gross examination, there is age-related degeneration of
septohippocampal cholinergic neurons and astrocytic
hypertrophy, markers of Alzheimer disease pathology that
are also present in elderly DS individuals.110 These findings
suggest that Ts65Dn mice may be useful to study certain
developmental and degenerative abnormalities in the DS
brain.
Cognitive impairment in transgenic mouse models of
amyloid deposition.
The identification of the Ab peptide as a major component
of amyloid deposited in brain vessels and subsequently of
parenchymal plaques in the brains of Alzheimer’s sub-
jects111 led to a focus on this molecule as a key element in
the pathophysiology of Alzheimer disease. Subsequent
work found that some mutations causing the disease
occurred in the amyloid precursor protein (APP) that is
processed, in some circumstances, into the Ab peptide.112
As for other disorders, development of animal models to
understand amyloid pathology became an important
research goal. Hsiao et al.113 were the first to demonstrate
that APP transgenic mice had both amyloid deposits and
memory deficit. They demonstrated deficits in a reference
memory version of the open-pool water maze,114 with the
deficits first appearing at an age when the amyloid plaques
started to appear (10–11 months). APP transgenic mice are a
very good model of amyloid deposition. The patterns of
deposition, regional distribution and even the anatomical
localization of the short and long variants mimic the human
disease. The APP mouse phenotype also consistently
includes progressive memory impairment. This phenotype
appears to be due to Ab accumulation and not over-
expression of APP, as the BACE1-null background, which
overproduces APP but not Ab, rescues the memory
phenotype.115 In addition, a number of manipulations, most
notably immunotherapies, have been found to regulate the
memory phenotype. However, the mechanisms mediating
memory deficiencies are not clear.
Cholinergic receptor knockout mice
The essential involvement of the cholinergic system in
both preclinical and clinical aspects of cognition processes
has been extensively proposed. The literature shows that
currently approved drugs for the treatment of Alzheimer
disease are cholinesterase inhibitors, which exert their
efficacy apparently through stimulation of both muscarinic
acetylcholine receptors (mAChRs) and nicotinic acetylcho-
line receptors (nAChRs).116,117 Transgenic and KO mouse
models are particularly useful for studies of complex
neurobiological problems such as mAChR KO mice,
nAChR KO mice as well as acetylcholinesterase (AChE)
KO mice. To illustrate, in the AChE –/– mice, the M(1), M(2)
and M(4) mAChRs showed a striking 50–80% decreased
expression in brain regions associated with memory.118 In
addition, a large body of evidence has demonstrated that
nicotine has a clinical utility for cognitive enhancement.
However, for most diseases in the central nervous system,
the coexistence of malfunctions in multiple subtypes of the
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same receptor or in multiple neurotransmitters typically
contribute to a complex phenotype such as cognition.117
Therefore, cholinergic-based strategies will likely remain
valid as one approach to understanding and to rational drug
development for the treatment of Alzheimer disease and
other forms of dementia and cognitive impairment.
CONCLUSION
ID is a lifelong condition and it is a daunting societal
problem. ID results from many different genetic and
environmental insults. Although tremendous progress has
been made, pharmacological intervention is currently still
non-existent and therapeutic strategies remain limited.
However, similarities across the spectrum of ID-related
disorders argue that common mechanisms underlie the
manifestation of learning and memory deficits in intellec-
tual disabled individuals. Interestingly, many of the
histological features noted in the brains of subjects with
DS parallel phenotypes that have been found in the brains of
individuals with other classes of ID, such as genetic
disorders, including inborn errors of metabolism and non-
genetic insults.5 Nevertheless, ID is a clinically important
disorder for which the etiology and pathogenesis are still
poorly understood. The past decades have seen extraordin-
ary progress in understanding, preventing and treating the
behavioral and cognitive deficits associated with ID.
Doubtless, animal models have been invaluable in ID
investigation, and continued progress will require program-
matic research. Progress in understanding and treating ID
will require translational research efforts. Translation
research means the transformation of knowledge through
successive fields of research from basic scientific discovery
to public health impact.
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